FIP1L1-PDGFRalpha Positive Hypereosinophilic Syndrome (HES). The Response to Imatinib (IM) Is Durable. A Report of 21 Patients with a Follow-Up of 12 to 67 Months.

Authors
Publication date
1 January 2006
Publisher
'American Society of Hematology'

Abstract

Abstract is not available.

    Similar works

    Full text

    thumbnail-image

    Available Versions

    Archivio istituzionale della ricerca - Università di Brescia

    redirect
    oaioai:iris.unibs.it:11379/31996
    Last time updated on 12/11/2016